Plural Carboxamide Groups Or Plural C=o Groups Bonded Directly To The Same Nitrogen Patents (Class 514/616)
-
Publication number: 20150065508Abstract: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.Type: ApplicationFiled: March 26, 2014Publication date: March 5, 2015Applicant: ABBVIE INC.Inventors: R. Scott Bitner, Kaitlin E. Browman, Michael E. Brune, Steven Fung, Peer B. Jacobson, Lynne E. Rueter, Marina I. Strakhova, Jiahong Wang, Jyoti R. Patel, Qi Shuai, James T. Link, Jeffrey J. Rohde, Jurgen Dinges, Bryan K. Sorensen, Martin Winn, Hong Yong, Vince S. Yeh
-
Publication number: 20150056305Abstract: Provided are dithiol mucolytic agents. These agents increase the liquefaction of mucus in a patient with excessive mucus or mucus with increased viscoelastic, cohesive, or adhesive properties. Also provided are a variety of methods of treatment using these inventive mucolytic agents.Type: ApplicationFiled: August 13, 2014Publication date: February 26, 2015Applicant: PARION SCIENCES, INC.Inventors: Michael R. Johnson, William R. Thelin, Ronald A. Aungst, JR.
-
Patent number: 8962546Abstract: This application provides methods of increasing vascularization, muscle performance, muscle rehabilitation, and/or mitochondrial activity in subjects in need thereof, by administering a therapeutically effective amount of one or more agents that increases ERR? activity to the subject. Such agents can include one or more ERR? agonists. In some examples the method does not require that the subject exercise, and as such, the subject may be sedentary (such as bedridden or in a wheelchair).Type: GrantFiled: March 1, 2012Date of Patent: February 24, 2015Assignee: Salk Institute for Biological StudiesInventors: Vihang A. Narkar, Michael Downes, Ruth T. Yu, Ronald M. Evans
-
Patent number: 8962690Abstract: A biocidal composition comprising 2,2-dibromomalonamide and a surface active biocide, and its use for the control of microorganisms in aqueous and water-containing systems.Type: GrantFiled: September 27, 2010Date of Patent: February 24, 2015Assignee: Dow Global Technologies LLCInventors: Bei Yin, Freddie L. Singleton
-
Publication number: 20150045367Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.Type: ApplicationFiled: December 19, 2012Publication date: February 12, 2015Inventors: Erik Verner, Wei Chen, Sriram Balasubramanian
-
Publication number: 20150038512Abstract: Compounds, compositions, and methods comprising a polyamine compound are described, which may be used to kill, disperse, treat, or reduce biofilms, or to inhibit or substantially prevent biofilm formation. In certain aspects, the present invention relates to compounds, compositions, and methods comprising polyamine compounds that have antimicrobial or dispersing activity against a variety of bacterial strains capable of forming biofilms.Type: ApplicationFiled: October 6, 2014Publication date: February 5, 2015Inventors: Ryan Looper, Dustin Williams, Sujeevini Jeyapalina, Travis Haussener, Paul R. Sebahar, Hariprasada R. Kanna Reddy
-
Publication number: 20150038586Abstract: This disclosure describes methods of use for N-acetylcysteine amide for the treatment of penetrating head injury.Type: ApplicationFiled: July 10, 2014Publication date: February 5, 2015Inventor: Glenn A. Goldstein
-
Patent number: 8946477Abstract: The invention relates to solid forms of the anti-epileptic agent lacosamide (I). The invention also relates to mixtures of solid forms of lacosamide. The invention further relates to mixtures of lacosamide enantiomers crystallized in a conglomerate Form and the use thereof in providing enantiomerically enriched lacosamide, preferably lacosamide enriched with the (R)-enantiomer of lacosamide.Type: GrantFiled: April 12, 2013Date of Patent: February 3, 2015Assignee: Medichem, S.A.Inventors: Ernesto Duran Lopez, Monica Benito Velez, Jordi Bosch i Lladó
-
Publication number: 20150030669Abstract: The present invention is directed to carrier systems comprising ether-lipids conjugated to one or more bioactive ligands and exposed on the surface of the carrier system for use in targeted delivery and/or antigen display systems. Optionally one or more further bioactive agents may be encapsulated or embedded within or attached to or adsorbed onto the carrier system. The present invention is further directed to methods of their preparation and their uses in medical applications, such as targeted delivery of bioactive agents to specific tissues or cells and antigen display systems for the study, diagnosis, and treatment of traits, diseases and conditions that respond to said bioactive agents.Type: ApplicationFiled: March 11, 2013Publication date: January 29, 2015Applicant: MERCK PATENT GMBHInventors: Michael Wilhelm Platscher, Raymond Behrendt, Viola Groehn, Simone Rachel Hoertner, Marco Silvio Passafaro, Finn Bauer
-
Publication number: 20150023868Abstract: The present invention is directed to HIF inhibitors and methods of preventing cell proliferation, reducing inflammation, and treating an angiogenic disease or disorders.Type: ApplicationFiled: February 21, 2014Publication date: January 22, 2015Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Othon Iliopoulos, Michael Zimmer
-
Patent number: 8933065Abstract: A first aspect of the invention is a compound (sometimes also referred to herein as an “active agent” or “active compound”) of Formula I or Ia: or a pharmaceutically acceptable salt or prodrug thereof. Compositions thereof and methods of using the same (e.g. for the treatment of a neurological disease) are also described.Type: GrantFiled: September 17, 2010Date of Patent: January 13, 2015Assignee: The University of North Carolina at Chapel HillInventors: Harold L. Kohn, Christophe Salomé, Ki Duk Park, Elise Salomé-Grosjean
-
Publication number: 20150011621Abstract: Formylated xanthocillin analogs can be used in the treatment of neurodegenerative diseases. The analogs can be prepared synthetically, and at least some of the analogs can be obtained from a microorganism strain of the Penicillium chrysogenum species.Type: ApplicationFiled: February 2, 2013Publication date: January 8, 2015Inventors: Maria del Carmen Ramos Martin, Sonia Campoy García, Javier Santos Burgos Muñoz, José Luis Adrio Fondevila, Javier Velasco Alvarez
-
Publication number: 20150011597Abstract: The invention is directed to compounds of formula I: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.Type: ApplicationFiled: March 27, 2014Publication date: January 8, 2015Applicant: THERAVANCE BIOPHARMA R&D IP, LLC.Inventors: Sharath Hegde, Daniel Marquess
-
Publication number: 20150005320Abstract: The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein X, Y, A, Z, L and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions and immune disorders.Type: ApplicationFiled: September 27, 2013Publication date: January 1, 2015Applicant: Synta Pharmaceuticals Corp.Inventors: Yu Xie, Mats Holmqvist, Jerome Mahiou, Mitsunori Ono, Lijun Sun, Shoujun Chen, Shijie Zhang, Jun Jiang, Dinesh Chimmanamada, Chih-Yi Yu
-
Publication number: 20140370080Abstract: The present invention relates generally to methods, compounds and compositions for treatment of adhesions, such as surgical adhesions.Type: ApplicationFiled: October 26, 2012Publication date: December 18, 2014Inventors: Arthur F. Stucchi, Michael Cassidy
-
Publication number: 20140370078Abstract: Compositions and methods are provided for the prevention and treatment of chronic wounds, including, without limitation, pressure ulcers and diabetic ulcers, by transdermal delivery of an agent that increases activity of HIF-1? in the wound.Type: ApplicationFiled: June 12, 2014Publication date: December 18, 2014Inventors: Geoffrey C. Gurtner, Jayakumar Rajadas, Michael Gabriel Galvez, Evgenios Neofytou
-
Patent number: 8906421Abstract: The present invention provides an aqueous composition and its use for dissolving blood clots in vivo or in clinical or research samples in vitro, said composition comprising at least one chaotropic agent, at least one chelating agent that complexes iron if the chaotropic agent does not complex iron and at least one surface-active emulsifier, the composition being buffered near pH 7.4. The process of dissolving the clot with the aqueous composition is advantageous because it is simple, inexpensive, rapid and can be applied in a variety of contexts, including basic research and clinical situations.Type: GrantFiled: June 21, 2012Date of Patent: December 9, 2014Assignee: MED-Genesis, LLCInventors: John S. Fisher, Fred Ahari, Christopher Jon Perry, Lucjan J. J. Hronowski
-
Publication number: 20140357628Abstract: Substituted cinnamoyl anthranilate compounds exhibiting anti-fibrotic activity; or derivatives thereof, analogues thereof, pharmaceutically acceptable salts thereof, and metabolites thereof, with the proviso that the compound is no Tranilast.Type: ApplicationFiled: June 27, 2014Publication date: December 4, 2014Applicant: Fibrotech Therapeutics Pty LtdInventors: Spencer John Williams, David Stapleton, Steven Zammit, Darren James Kelly, Richard Ernest Gilbert, Henry Krum
-
Publication number: 20140350102Abstract: This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; metastasis in a subject suffering from breast cancer; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.Type: ApplicationFiled: June 2, 2014Publication date: November 27, 2014Applicant: GTx, Inc.Inventors: James T. Dalton, Mitchell S. Steiner, Ramesh Narayanan, Sunjoo Ahn
-
Publication number: 20140350113Abstract: Described herein are small-molecule mimics of CD4, which both enter the Phe43 cavity and target Asp368 of gp120, the HIV-1 envelope protein. Also described herein are methods of using these compounds to inhibit the transmission or progression of HIV infection. These compounds exhibit antiviral potency greater than that of a known antiviral, NBD-556, with 100% breadth against clade B and C viruses. Importantly, the compounds do not activate HIV infection of CD4-negative, CCR5-positive cells, in contrast to NBD-556.Type: ApplicationFiled: December 14, 2012Publication date: November 27, 2014Inventors: Joseph Sodroski, Judith M. LaLonde, Amos B. Smith, III, Peter D. Kwong, Young Do Kwon, David M. Jones, Alexander W. Sun, Joel R. Courter, Takahiro Soeta, Toyoharu Kobayashi, Amy M. Princiotto, Xueling Wu, John R. Mascola, Ame Schon, Emesto Freire, Navid Madani, Matthew Le-Khac, Wayne A. Hendrickson
-
Publication number: 20140343101Abstract: Disclosed are methods and compositions for modulating the function of transcription factors, especially transcription factors that recruit epigenetic regulators (histone modifying enzymes) to specific DNA promoters. The targeted transcription factors include but are not limited to the myocyte enhancing factor (MEF2), the forkhead/winged helix transcription factor FOXP3 and the transcription factor GATA3.Type: ApplicationFiled: February 26, 2014Publication date: November 20, 2014Applicant: UNIVERSITY OF SOUTHERN CALIFORNIAInventors: Lin Chen, Nimanthi Jayathilaka, Aidong Han, Nicos A. Petasis
-
Patent number: 8889163Abstract: Facially amphiphilic polyphenylene and heteroarylene polymers and articles made therform having biocidal surfaces are disclosed. The polymers can inhibit the growth of microorganisms in contact with the surface or in areas adjacent to said biocidal surface. There is also disclosed a methods to attach facially amphiphilic polmers to a solid support. Utility as a contact disinfectant is disclosed.Type: GrantFiled: March 7, 2002Date of Patent: November 18, 2014Assignee: The Trustees of the University of PennsylvaniaInventors: William F. DeGrado, Gregory N. Tew, Michael L. Klein
-
Patent number: 8889678Abstract: The present invention relates to acyl guanidine derivatives modulating the hedgehog protein signaling pathway to be used as drugs, in particular for treating diseases involving a tissue dysfunction associated with a deregulation of the hedgehog protein signaling pathway, as well as to pharmaceutical compositions containing same. The present invention also relates to novel acyl guanidine derivatives as such.Type: GrantFiled: July 19, 2010Date of Patent: November 18, 2014Assignees: Centre National de la Recherche Scientifique, Universite de StrasbourgInventors: Martial Ruat, Hélène Faure, Elisabeth Traiffort, Hermine Roudaut, André Mann, Angèle Schoenfelder, Maurizio Taddei, Fabrizio Manetti, Antonio Solinas
-
Publication number: 20140336187Abstract: Methods are provided to inhibit proliferation of Leishmania parasites, and in particular Leshmania donovani with imido-substituted 1,4-naphthoquinones, including novel compounds. Administering an imido-substituted 1,4-naphthoquinone can used to provide prophylaxis or treatment to a patient in need of treatment against leishmaniasis disease.Type: ApplicationFiled: November 16, 2012Publication date: November 13, 2014Inventors: Oladapo Bakare, Clarence M. Lee, Yakini Brandy, Cheu Manka
-
Publication number: 20140323568Abstract: The present invention includes bis- and tris-benzamide compounds that block AR signaling and have activity against prostate cancer. Uses for these compounds, and pharmaceutical compositions containing the same, also are provided.Type: ApplicationFiled: April 23, 2014Publication date: October 30, 2014Applicant: The Board of Regents of the University of Texas SystemInventors: Jung-Mo AHN, Ganesh RAJ
-
Publication number: 20140323390Abstract: The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.Type: ApplicationFiled: July 9, 2014Publication date: October 30, 2014Applicant: IRM LLCInventors: Tom Yao-Hsiang WU, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan
-
Patent number: 8871208Abstract: A method for treating a patient suffering from inflammation, chronic inflammation, pain, rheumatoid arthritis (RA), osteoarthritis and osteoporosis, comprising administering an effective amount of a selective inhibitor of the 11-?-hydroxysteroid dehydrogenase Type 1 enzyme.Type: GrantFiled: December 2, 2010Date of Patent: October 28, 2014Assignee: AbbVie Inc.Inventors: Peer B. Jacobson, Lisa M. Olson, Sreeinvasarao Vepachedu
-
Publication number: 20140308241Abstract: Described are biomarkers including TOX useful for the diagnosis or prognosis of T cell malignancy. A level of a biomarker is determined in a sample from a subject and compared to a control level, wherein an increased level of the biomarker in the sample relative to the control level indicates that the subject has T cell malignancy. The T cell malignancy may be a cutaneous T cell lymphoma (CTCL) such as mycosis fungoides or Sezary syndrome.Type: ApplicationFiled: November 16, 2012Publication date: October 16, 2014Inventors: Youwen Zhou, Yuanshen Huang, Yang Wang, Ming-wan Su
-
Patent number: 8859605Abstract: Compounds of the formula I wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10 alkyl chain, C2-C4haloalkyl or —CH2C3-C7 cycloalkyl; R4 is C1-C6alkyl, C1-C6haloalkyl, C1-C6alkylamino or C1-C6dialkylamino; for use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.Type: GrantFiled: December 10, 2010Date of Patent: October 14, 2014Assignee: Medivir UK LtdInventors: Susana Ayesa, Peter Carlqvist, Karolina Ersmark, Urszula Grabowska, Ellen Hewitt, Daniel Jonsson, Pia Kahnberg, Bjorn Klasson, Peter Lind, Lourdes Oden, Kevin Parkes, Daniel Wiktelius
-
Patent number: 8859590Abstract: Inhibitors of BACE1 and compositions containing them are described. Use of the inhibitors and compositions containing them to treat Alzheimer's disease are described.Type: GrantFiled: December 4, 2009Date of Patent: October 14, 2014Assignee: Purdue Research FoundationInventor: Arun K. Ghosh
-
Patent number: 8853281Abstract: Compounds of the formula I wherein R1a is H; and R1b is C1-C6 alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are H, halo, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy; or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10alkyl chain, C2-C4haloalkyl or C3-C7cycloalkylmethyl, R4 is Het, Carbocyclyl, optionally substituted as defined in the specification and pharmaceutically acceptable salts, hydrates and N-oxides thereof; are inhibitors of cathepsin S and have utility in the treatment of psoriasis, autoimmune disorders and other disorders such as asthma, arteriosclerosis, COPD and chronic pain.Type: GrantFiled: December 18, 2009Date of Patent: October 7, 2014Assignee: Medivir UK LtdInventors: Susana Ayesa, Anna Karin Belfrage, Bjorn Classon, Urszula Grabowska, Ellen Hewitt, Vladimir Ivanov, Daniel Jönsson, Pia Kahnberg, Peter Lind, Magnus Nilsson, Lourdes Odén, Mikael Pelcman, Horst Wähling
-
Patent number: 8853452Abstract: Compounds and their syntheses are disclosed herein. Compositions and pharmaceutical compositions comprising a compound are also described, and include compositions also comprising liposomes. Methods for the treatment of cancer in animals comprising administering a compound or a composition comprising a compound are also described.Type: GrantFiled: February 9, 2010Date of Patent: October 7, 2014Assignee: The Administrators of the Tulane Educational FundInventors: Barbara S. Beckman, Maryam Foroozesh, Jiawang Liu
-
Publication number: 20140296294Abstract: Cannabionid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof: wherein: R1 and R2 are independently H, alkyl, or alkenyl; R3 is alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; R4 and R5 are independently a bond, alkylenyl, or alkenylenyl; each R6 and R7 is independently selected from the group consisting of OH, F, Cl, Br, I, (C1-C6)alkyl, alkoxy, amino, COOH, CONH2, SO3H, PO3H2, CN, SH, NO2 and CF3; and p and q are independently 0, 1, 2, 3, 4, or 5. Such compounds may be used to treat osteoporosis or multiple myeloma.Type: ApplicationFiled: June 16, 2014Publication date: October 2, 2014Inventors: Xiang-qun XIE, Peng YANG, Rentian FENG
-
Publication number: 20140296344Abstract: There are provided various polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds can be useful as cancer chemopreventive agents, cancer treating agent, inhibiting tumor growth or cell proliferation, reducing tumor growth or as radioenhencers for radiotherapy of cancer.Type: ApplicationFiled: June 13, 2014Publication date: October 2, 2014Inventor: Samuel FORTIN
-
Publication number: 20140296343Abstract: Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule.Type: ApplicationFiled: March 31, 2014Publication date: October 2, 2014Inventors: Frank M. LONGO, Stephen M. MASSA, Sandeep GUPTA
-
Patent number: 8846720Abstract: The present invention provides a composition having an excellent controlling activity on a pest. The composition comprising a compound represented by Formula (1) and one or more diamide compound(s) selected from Group (A) shows an excellent controlling activity on a pest.Type: GrantFiled: October 13, 2011Date of Patent: September 30, 2014Assignee: Sumitomo Chemical Company, LimitedInventors: So Kiguchi, Soichi Tanaka
-
Patent number: 8846932Abstract: Disclosed are methods and compositions for modulating the function of transcription factors, especially transcription factors that recruit epigenetic regulators (histone modifying enzymes) to specific DNA promoters. The targeted transcription factors include but are not limited to the myocyte enhancing factor (MEF2), the forkhead/winged helix transcription factor FOXP3 and the transcription factor GATA3. Also disclosed are small molecule modulators of MEF2 and its associated factors that include but not limited to histone deacetylases (HDACs), p300/CBP and Cabin1 and the therapeutic applications thereof.Type: GrantFiled: March 13, 2013Date of Patent: September 30, 2014Assignee: University of Southern CaliforniaInventors: Lin Chen, Nimanthi Jayathilaka, Aidong Han, Nicos A. Petasis
-
Publication number: 20140288077Abstract: In one aspect, the invention relates to substituted 4-phenoxyphenol analogs, derivatives thereof, and related compounds, which are useful as inhibitors of proliferating cell nuclear antigen (PCNA); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating hyperproliferative disorders associated with PCNA using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: July 5, 2012Publication date: September 25, 2014Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITALInventors: Naoaki Fujii, Marcelo Actis, Chandanamali Punchihewa, Michele Connelly, Sean Wu
-
Publication number: 20140288087Abstract: The disclosure provides methods for determining the self-renewal potential of a cancer stem cell (CSC), or for predicting the drugability (susceptibility to a drug) of a CSC, and/or for predicting the progression of a cancer that corresponds to the CSC. In alternative embodiments, the disclosure provides methods for determining whether a CSC in a niche is more pro-apoptotic or more anti-apoptotic in relation to a normal stem cell or a CSC from another niche. In alternative embodiments, the disclosure provides methods for determining the prognosis or malignant potential of a cancer. In alternative embodiments, the disclosure provides methods determining the anti-apoptotic versus a pro-apoptotic potential of a cancer stem cell (CSC).Type: ApplicationFiled: November 7, 2012Publication date: September 25, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Catriona M. Jamieson, Daniel Goff, Kristen Smith
-
Publication number: 20140288183Abstract: This invention relates to the use of bis- and tris-dihydroxyaryl compounds as well as sulfonamides, heteroaryls, tricycloalkyl and their analogs and pharmaceutically acceptable salts, for modulating tau aggregation and alleviating tauopathies, such as Alzheimer's disease (AD), Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and familial frontotemporal dementia/Parkinsonism linked to chromosome 17 (FTDP-17), amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia.Type: ApplicationFiled: June 10, 2014Publication date: September 25, 2014Inventors: Alan D. Snow, Qubai Hu, Thomas Lake, Judy Cam
-
Patent number: 8841328Abstract: The present invention relates to the use of selective insecticidal compositions, characterized by an effective amount of an active compound combination comprising (a) (1) at least one haloalkylnicotinic acid derivative of the formula (I) in which AA and R1A are as defined in the description, or (2) at least one phthalic acid diamide of the formula (II) in which XB, R1B, R2B, R3B, L1B, L2B and L3B are as defined in the description, or (3) at least one anthranilamide of the formula (III) in which A1C, A2C, XC, R1C, R2C, R3C, R4C, R5C, R7C, R8C and R9C are as defined in the description, and (b) at least one crop plant compatibility-improving compound from the group of compounds given in the description, in particular cloquintocet-mexyl, isoxadifen-ethyl and mefenpyr-diethyl for controlling insects and/or arachnids, and a method for controlling insects and/or arachnids using the compositions.Type: GrantFiled: December 3, 2013Date of Patent: September 23, 2014Assignee: Bayer CropScience AGInventors: Reiner Fischer, Rüdiger Fischer, Christian Funke, Achim Hense, Wolfram Andersch, Heike Hungenberg, Wolfgang Thielert, Udo Reckmann, Lothar Willms, Christian Arnold
-
Patent number: 8841346Abstract: The invention relates to methods and compositions for promoting cognitive function and/or treating cognitive function disorders and impairments. In particular the methods are accomplished by administering to a subject CI-994 or dinaline or a pharmaceutically acceptable salt, ester, prodrug or metabolite thereof.Type: GrantFiled: August 27, 2012Date of Patent: September 23, 2014Assignees: Massachusetts Institute of Technology, The Broad Institute, Inc., The General Hospital CorporationInventors: Li-Huei Tsai, Ji-Song Guan, Stephen J. Haggarty, Edward Holson, Florence Wagner, Johannes Graeff
-
Publication number: 20140275268Abstract: Novel solid forms of tacedinaline (4-(acetylamino)-N-(2-aminophenyl)benzamide), including crystalline tacedinaline Form B, a novel crystalline tacedinaline TFA salt, and amorphous tacedinaline, are disclosed. Pharmaceutical compositions comprising crystalline tacedinaline Form B, the novel crystalline tacedinaline TFA salt, and/or amorphous tacedinaline, and methods of treating various conditions by administering those novel solid forms, are also disclosed.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: THE BROAD INSTITUTE, INC.Inventors: Edward Holson, Florence F. Wagner, G. Patrick Stahly
-
Publication number: 20140275269Abstract: Disclosed are 5-nitrobenzoate derivatives of Formula I, and the preparation method therefor, wherein R is referred to hydrogen (H), unsubstituted, mono-substituted, di-substituted or tri-substituted benzoyl moiety. 5-Nitrobenzoare derivatives of Formula I do not affect the platelet aggregation, possesses the inhibitory activity related to the tumor cell-induced platelet aggregation (TCIPA), and further specifically inhibits podoplanin-induced platelet aggregation. Therefore, 5-nitrobenzoates of the invention are applicable in its therapeutic use as the novel therapeutic agent in preventing tumor metastasis.Type: ApplicationFiled: May 27, 2014Publication date: September 18, 2014Applicant: CHANG GUNG UNIVERSITYInventors: Ching-Ping TSENG, Pei-Wen HSIEH, Yao-Wen CHANG
-
Publication number: 20140271825Abstract: The present invention provides liposomes loaded with chelating agents, pharmaceutical formulations including these liposomes and methods of making chelating agent liposomes. Because the chelating agents are loaded in the liposome with high efficiencies, the liposomes are of use in treatment of metal ion overload in subjects. The liposomes can include two or more different chelating agents of different structures and affinities for metal ions.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Inventors: Mark E. HAYES, Charles O. NOBLE, Francis C. SZOKA, JR.
-
Patent number: 8835502Abstract: The invention provides methods of treating Friedreich's ataxia using histone deacetylase inhibitors.Type: GrantFiled: April 15, 2013Date of Patent: September 16, 2014Assignee: The Scripps Research InstituteInventors: Joel M. Gottesfeld, Kai Jenssen, David M. Herman, Ryan Burnett, C. James Chou
-
Publication number: 20140256817Abstract: Small-molecule scaffolds based on 1,2-diphenylacetylene that accurately replicate the spatial and angular projections of several side chains on both faces of an ?-helix, specifically the i and i+7 side chains on one face, and the i and i+2 side chains on the other. The amphipathic ?-helix mimetic can be used to disrupt disease-promoting protein-protein interactions that are mediated by ?-helices.Type: ApplicationFiled: March 7, 2014Publication date: September 11, 2014Applicant: UNIVERSITY OF MARYLAND, BALTIMOREInventor: Steven FLETCHER
-
Publication number: 20140256698Abstract: The present invention is directed to inhibitors of cathepsins and the methods for using and making such inhibitors.Type: ApplicationFiled: March 11, 2014Publication date: September 11, 2014Inventors: Robert Booth, Jeff Dener, Michael Green
-
Publication number: 20140256776Abstract: The present disclosure provides novel methods for treating cancer and conditions regulatable by a transcription factor and/or cofactor using specific compounds, as well as compositions, and pharmaceutical formulations. In certain embodiments, the compounds are transcription factor modulators.Type: ApplicationFiled: March 15, 2013Publication date: September 11, 2014Inventors: Lin CHEN, Xiaojiang CHEN, Meng XIA, Yongqing WU, Yongheng CHEN, Dahai GAI
-
Publication number: 20140256775Abstract: The present disclosure provides novel compounds capable of functioning as transcription factor modulators, as well as compositions, pharmaceutical formulations, and kits. Also provided are methods of treating a condition regulatable by a transcription factor and/or cofactor using the compounds, compositions, pharmaceutical formulations, and kits provided herein.Type: ApplicationFiled: March 15, 2013Publication date: September 11, 2014Inventors: Lin CHEN, Xiaojiang CHEN, Yongqing WU, Dahai GAI